The UK Patents Court has referred four questions to the Court of Justice of the European Union (CJEU) seeking clarification on how the Supplementary Protection Certificate (SPC) Regulation should be interpreted in relation to drug products made of a combination of active ingredients.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on firstname.lastname@example.org.
SPC, CJEU, Actavis, Boehringer Ingelheim, MicardisPlus